TriangleTebentafusp-Tebn (NCT06414590)
Tebentafusp-Tebn trial for Locally Advanced Unresectable Uveal Melanoma (NCT06414590). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated T3 or T4 uveal melanoma that cannot be removed without removing the eye. HLA-A*02:01 positivity is required. Metastatic disease or urgent eye intervention excludes entry.
The idea: tebentafusp connects T cells with gp100-bearing cancer cells. Weekly infusions for up to eight weeks precede plaque radiation or eye removal, as the doctor decides. Tumor biopsies are required. Researchers assess shrinkage and eye toxicity; preserving sight is exploratory.
This phase 2 study plans 19 patients. Rino Seedor leads at Thomas Jefferson University, Philadelphia, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.